Impetigo
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2], Cafer Zorkun, M.D., Ph.D. [3]
Synonyms and keywords: Impetigo contagiosa; Pyoderma; Bullous impetigo; Non-bullous impetigo; Primary impetigo; Secondary impetigo; Ecthyma; School sores
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Impetigo is a contagious superficial, bacterial skin infection most common among children age 2–6 years. People who play close contact sports such as rugby, American football and wrestling are also susceptible, regardless of age. The name derives from the Latin impetere (“assail”). It is also known as school sores. Skin is normally colonized with a large number of pathogens. When the pathogens increase in number on the skin or when there is a break in the continuity ofthe skin, they can lead to an infection.[1][2]
Historical Perspective
In 1880, Alexander Ogston for the first time wrote about the involvement of Staphylococci in skin infections.In 1863, R. W. Dunn of Porrigo described lesions of impetigo as dirty, flat, irregular spots that are straw coloured.[3] The first epidemic in the nurseries was reported in 1989.[4]
Classification
Impetigo can be classified in various ways. It can be classified as bullous, non-bullous and ecthyma. It can also be classified as primary or secondary to a disease or process. Another classification pattern is with respect to the involved pathogen as staphylococcal or streptococcal impetigo. Non-bullous impetigo also known as “impetigo contagiosa” is caused by both Staphylococci and Streptococci and is estimated to make almost 70% of its cases.[5]
Pathophysiology
Impetigo is spread by direct lesion contact. The incubation period is 1–3 days and 4-10 days for for Streptococci and Staphylococci respectively. Bullous impetigo is caused by exfoliative toxins which are released by Stapphylococcus aureus. The toxins are of two types, A and B, and lead to the production of bullae in the superficial layer of epidermis.[6]
Causes
Impetigo is usually caused by Staphylococcus aureus. Streptococci (e.g. Streptococcus pyogenes) have been associated with the non-bullous form of impetigo and ecthyma.Streptococci can either infect individually or co-infect with Staphylococcus aureus. Non-bullous impetigo makes 70% of all the caess of impetigo.[7][8][9][5]
Differentiating Impetigo from other Diseases
Impetigo must be differentiated from other diseases that cause pustules surrounded by erythematous skin, including chickenpox, herpes zoster, erythema multiforme, among others. It should be differentiated from scabies, contact dermatitis, lupus (discoid type), herpes simplex, burns, necrotizing faciitis.[10]
Epidemiology and Demographics
In 2010, 140 million people suffered from impetigo. Impetigo is more common among children. Impetigo is more prevalent in tropical and pacific countries.[11][12][13]
Risk Factors
Impetigo is often associated with insect bites, cuts, and other forms of trauma to the skin. Humidity, obesity, corticosteroid use, chemotherapy, dysglobulinemias, leukemias and malnutrition are some other risk factors for impetigo.[14] Handwashing decreseas the incidence of impetigo by 34%.[15]
Screening
The United States Preventive Services Task Force (USPSTF) has not issued any guidelines for the screening of impetigo.
Natural History, Complications and Prognosis
If left untreated, most cases of non-bullous impetigo resolve within 1-2 weeks. The complications of impetigo include poststreptococcal glomerulonephritis and rheumatic fever.[16][17][18][19][20]
Diagnosis
History and Symptoms
PImptigo has a conatgious course. People who suffer from cold sores have shown higher chances of suffering from impetigo. Patients with impetigo usualy have a history of recurrent lesions, immunodeficiency and trauma or abrasions. Symptoms may vary from vesicles to bullae that can be seen localized in early disease or spread to trunk and extremities if not taken care of. Fever and fatigue are important symtoms associated with seeking medical attention.[5][21]
Patients may present with one or more pimple-like lesions surrounded by reddened skin. Lesions fill with pus, then break down over 4–6 days and form a thick crust. Impetigo is often associated with insect bites, cuts, and other forms of trauma to the skin. Itching is common.[5]
Physical Examination
The diagnosis of impetigo is primarily clinical. A thorough physical examination plays an important role in the diagnosis of impetigo along with a detailed history taking.Bullae, papules, pustules or ulcers may be visible depicting various types of impetigo.[19][5]
Laboratory Findings
Impetigo is primarily diagnosed clinically. Some laboratory tests can also be used to confirm the involved pathogen and to focus the treatment on that pathogen in particular. These include gram stain and culture and senstivity.[19][2]
Xray
Xrays do not contribute in the diagnosis of impetigo.
CT Scan
CT scan does not contribute in the diagnosis of impetigo.
MRI
MRI does not contribute in the diagnosis of impetigo.
Ultrasound
Ultrasound does not contribute in the diagnosis of impetigo.
Other Imaging Findings
Other imaging findings do not contribute in the diagnosis of impetigo.
Other Diagnostic Studies
Immunodeficiency can be evaluated in case of recurrence of impetigo. Other aspects may involve a detailed review of conditions like malnutrition, leukemia and diabetes.
Treatment
The treatment of impetigo is primarily medical.
Medical Therapy
The mainstay of therapy for impetigo is antimicrobial therapy. Empiric therapy for mild disease includes either Mupirocin or Retapamulin applied topically. Empiric therapy for numerous lesions or poststreptococcoal glomerulonephritis includes either Dicloxacillin, Amoxicillin-Clavulanate, or Cephalexin. Penicillin is the drug of choice for impetigo caused by Streptococcus. Patients with impetigo caused by Methicillin-resistant Staphylococcus aureus are treated with either Doxycycline, Clindamycin, or Sulfamethoxazole-Trimethoprim. Non-bullous impetigo is self resolving and usually takes 1-2 weeks.[5][22]Topical or oral antibiotics are usually prescribed.
Surgery
Medical therapy is the primary mode of treatment for impetigo. Surgery is not usually required. Biopsy may sometimes be required if there is recurrence of lesions and the diagnosis of impetigo is not confimed.[23]
Primary Prevention
Primary prevention of impetigo involves various aspect of ensuring hygiene including avoiding prolonged exposures to dirty environments , handwashing and regular bathing. Handwashing alone can decrease the incidence of impetigo by 34%.[15]
Secondary Prevention
The measure for secondary prevention of impetigo include avoidance of scratching, keeping the lesions covered, nails must be cut to avoid spread and keepig towel separate is also recommended.
References
- ↑ Oumeish I, Oumeish OY, Bataineh O (2000). “Acute bacterial skin infections in children”. Clin Dermatol. 18 (6): 667–78. PMID 11173202.
- ↑ 2.0 2.1 Ibrahim F, Khan T, Pujalte GG (2015). “Bacterial Skin Infections”. Prim Care. 42 (4): 485–99. doi:10.1016/j.pop.2015.08.001. PMID 26612370.
- ↑ Template:Fox, W. Tilbury. “On impetigo contagiosa, or porrigo.” British medical journal 1.174 (1864): 467.
- ↑ “Classics in infectious diseases. “On abscesses”. Alexander Ogston (1844-1929)”. Rev Infect Dis. 6 (1): 122–8. 1984. PMID 6369479.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 Cole C, Gazewood J (2007). “Diagnosis and treatment of impetigo”. Am Fam Physician. 75 (6): 859–64. PMID 17390597.
- ↑ “ISDH: Impetigo”.
- ↑ Darmstadt GL, Lane AT (1994). “Impetigo: an overview”. Pediatr Dermatol. 11 (4): 293–303. PMID 7899177.
- ↑ Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC (1990). “Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies”. Am J Dis Child. 144 (12): 1313–5. PMID 2244610.
- ↑ Invalid
<ref>tag; no text was provided for refs named:0 - ↑ Hartman-Adams H, Banvard C, Juckett G (2014). “Impetigo: diagnosis and treatment”. Am Fam Physician. 90 (4): 229–35. PMID 25250996.
- ↑ “High Burden of Impetigo and Scabies in a Tropical Country”.
- ↑ Romani L, Steer AC, Whitfeld MJ, Kaldor JM (2015). “Prevalence of scabies and impetigo worldwide: a systematic review”. Lancet Infect Dis. 15 (8): 960–7. doi:10.1016/S1473-3099(15)00132-2. PMID 26088526.
- ↑ Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M; et al. (2012). “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet. 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
- ↑ Carroll JA (1996). “Common bacterial pyodermas. Taking aim against the most likely pathogens”. Postgrad Med. 100 (3): 311–3, 317–22. doi:10.3810/pgm.1996.09.84. PMID 8795661.
- ↑ 15.0 15.1 Luby SP, Agboatwalla M, Feikin DR, Painter J, Billhimer W, Altaf A; et al. (2005). “Effect of handwashing on child health: a randomised controlled trial”. Lancet. 366 (9481): 225–33. doi:10.1016/S0140-6736(05)66912-7. PMID 16023513. Review in: Evid Based Med. 2006 Jun;11(3):88
- ↑ McDonald MI, Towers RJ, Andrews RM, Benger N, Currie BJ, Carapetis JR (2006). “Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic”. Clin Infect Dis. 43 (6): 683–9. doi:10.1086/506938. PMID 16912939.
- ↑ Weinstein L, Le Frock J (1971). “Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomerulonephritis?”. J Infect Dis. 124 (2): 229–31. PMID 4942062.
- ↑ Cohen PR (2016). “Bullous impetigo and pregnancy: Case report and review of blistering conditions in pregnancy”. Dermatol Online J. 22 (4). PMID 27617460.
- ↑ 19.0 19.1 19.2 Duggal SD, Bharara T, Jena PP, Kumar A, Sharma A, Gur R; et al. (2016). “Staphylococcal bullous impetigo in a neonate”. World J Clin Cases. 4 (7): 191–4. doi:10.12998/wjcc.v4.i7.191. PMC 4945591. PMID 27458596.
- ↑ Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ (2011). “Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis”. Pediatr Nephrol. 26 (2): 165–80. doi:10.1007/s00467-010-1554-6. PMID 20652330.
- ↑ Adams BB (2002). “Dermatologic disorders of the athlete”. Sports Med. 32 (5): 309–21. PMID 11929358.
- ↑ Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC; et al. (2012). “Interventions for impetigo”. Cochrane Database Syst Rev. 1: CD003261. doi:10.1002/14651858.CD003261.pub3. PMID 22258953.
- ↑ Geria AN, Schwartz RA (2010). “Impetigo update: new challenges in the era of methicillin resistance”. Cutis. 85 (2): 65–70. PMID 20349679.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Impetigo is spread by direct contact with the lesion. The incubation period is 1–3 days and 4-10 days for for Streptococci and Staphylococci respectively. Bullous impetigo is caused by exfoliative toxins which are released by Staphylococcus aureus. The toxins are of two types, A and B, and lead to the production of bullae in the superficial layer of epidermis.[1]
Pathogenesis
Impetigo, the infection of epidermis, can either be primary or secondary to scratches, injuries, bites or conditions that lead to a break in the continuity of the skin. The breaks in the continuity are potential sites for the pathogens to enter and infect.[2][3][4][5]
Streptococcal Impetigo
- The D and E strains of emm protein act as a virulence factor for group A streptococci.[2][6]
- Group A Streptococci have great invasive potential. They can be isolated from the skin 10 days before an infection and from the oropharynx, 2-3 weeks after the appearance on the skin.[7]
Staphylococcal Impetigo
Staphylococci cause toxin mediated impetigo in the following way:[8]
- Staphylococci produce toxins that act as superantigens.
- These superantigens can activate T-lymphocytes.
- The exfoliative toxins produced can hydrolyze desmoglein 1 and thus weaken the desmosomes.
- They can also produce IL-1 and IL-6 and tumor necrosis factor alpha (TNF-a).
- These lymphokines can act on the skin producing bullous impetigo.
Bullous Impetigo
The following are important aspects in the pathogenesis of bullous impetigo:[9][10][4]
- Bullous impetigo is caused by exfoliative toxins which are released by Stapphylococcus aureus.
- The exfoliative toxins can hydrolyze desmoglein 1 and thus weaken the desmosomes.
- The toxins are of two types, A and B, and lead to the production of bullae in the superficial layer of epidermis.
- These bullae are flaccid and can rupture easily.
Non-bullous Impetigo
The pathogenesis of non-bulbous impetigo involves:[11]
- Staphylococcus aureus is involved in almost 80% cases.
- Group A streptococci also contribute in the pathogenesis either alone or in combination with Staphylococcus aureus.
- Toxins are produced by the bacteria which act as superantigens.
- Activation of T-lymphocytes and the production of IL-1, IL-6 and TNF-a is mediated by the toxins.
- These lead to exfoliative skin changes and thus impetigo.
Ecthyma
The pathogenesis of ecthyma involves:[12]
- Infection is usually caused by Streptococcus pyogenes.
- Immunodeficient individuals have a higher risk of ecthyma.
- The deficiency of antibody that opsonizes the S. pyogenes M protein is main step in pathogenesis.
- The lesions are painful and filled with pus.
- The lesions extend into the epidermis and thus an ulcer is formed after the rupture of the lesion.
- The surface of the ulcer is covered with a brown scab.
Genetic
Impetigo associated with group A streptococci is understood to have a genetic basis and is associated with subfamilies of emm gene.[6]
Associated Conditions
The conditions associated with impetigo include:[13][11]
- Diabetes
- Immunodeficiency
- Eczema
- Diseases associated with rash
- Cellulitis
- Dermatological disorders of all kinds
- Trauma
- Atopic dermatitis
- Contact dermatitis
- Pediculosis
Gross Pathology
Face

Trunk/Axillae

Golden Crusting

Microscopic Pathology
Microscopic pathology findings are not significant for the diagnosis or treatment of impetigo.
References
- ↑ “ISDH: Impetigo”.
- ↑ 2.0 2.1 Wasserzug O, Valinsky L, Klement E, Bar-Zeev Y, Davidovitch N, Orr N; et al. (2009). “A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes”. Clin Infect Dis. 48 (9): 1213–9. doi:10.1086/597770. PMID 19331587.
- ↑ Bangert S, Levy M, Hebert AA (2012). “Bacterial resistance and impetigo treatment trends: a review”. Pediatr Dermatol. 29 (3): 243–8. doi:10.1111/j.1525-1470.2011.01700.x. PMID 22299710.
- ↑ 4.0 4.1 Kato F, Kadomoto N, Iwamoto Y, Bunai K, Komatsuzawa H, Sugai M (2011). “Regulatory mechanism for exfoliative toxin production in Staphylococcus aureus”. Infect Immun. 79 (4): 1660–70. doi:10.1128/IAI.00872-10. PMC 3067547. PMID 21282415.
- ↑ Nishifuji K, Shimizu A, Ishiko A, Iwasaki T, Amagai M (2010). “Removal of amino-terminal extracellular domains of desmoglein 1 by staphylococcal exfoliative toxin is sufficient to initiate epidermal blister formation”. J Dermatol Sci. 59 (3): 184–91. doi:10.1016/j.jdermsci.2010.07.010. PMID 20728315.
- ↑ 6.0 6.1 Bessen DE, Sotir CM, Readdy TL, Hollingshead SK (1996). “Genetic correlates of throat and skin isolates of group A streptococci”. J Infect Dis. 173 (4): 896–900. PMID 8603968.
- ↑ Lin JN, Chang LL, Lai CH, Lin HH, Chen YH (2011). “Clinical and molecular characteristics of invasive and noninvasive skin and soft tissue infections caused by group A Streptococcus”. J Clin Microbiol. 49 (10): 3632–7. doi:10.1128/JCM.00531-11. PMC 3187321. PMID 21865425.
- ↑ Manders SM (1998). “Toxin-mediated streptococcal and staphylococcal disease”. J Am Acad Dermatol. 39 (3): 383–98, quiz 399-400. PMID 9738772.
- ↑ Cohen PR (2016). “Bullous impetigo and pregnancy: Case report and review of blistering conditions in pregnancy”. Dermatol Online J. 22 (4). PMID 27617460.
- ↑ Duggal SD, Bharara T, Jena PP, Kumar A, Sharma A, Gur R; et al. (2016). “Staphylococcal bullous impetigo in a neonate”. World J Clin Cases. 4 (7): 191–4. doi:10.12998/wjcc.v4.i7.191. PMC 4945591. PMID 27458596.
- ↑ 11.0 11.1 Pereira LB (2014). “Impetigo – review”. An Bras Dermatol. 89 (2): 293–9. PMC 4008061. PMID 24770507.
- ↑ Hewitt WD, Farrar WE (1988). “Bacteremia and ecthyma caused by Streptococcus pyogenes in a patient with acquired immunodeficiency syndrome”. Am J Med Sci. 295 (1): 52–4. PMID 3276190.
- ↑ Hartman-Adams H, Banvard C, Juckett G (2014). “Impetigo: diagnosis and treatment”. Am Fam Physician. 90 (4): 229–35. PMID 25250996.
- ↑ 14.0 14.1 14.2 “Dermatology Atlas”.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Impetigo is usually caused by Staphylococcus aureus. Streptococci (e.g. Streptococcus pyogenes) have been associated with the non-bullous form of impetigo and ecthyma.Streptococci can either infect individually or co-infect with Staphylococcus aureus. Non-bullous impetigo makes 70% of all the caess of impetigo.[1][2][3][4]
Causes
It was previously believed that non-bullous impetigo is caused by group A streptococci whereas Staphylococcus aureus causes the bullous subtype of impetigo. Both bullous and non-bullous subtypes of impetigo are now understood to be primarily caused by S. aureus. Streptococci have been associated with the non-bullous form and ecthyma.[3][5][6][7]
Common causes
The common causes of impetigo include:[8][9][10][11]
- Staphylococcus aureus
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Gentamicin-resistant Staphylococcus aureus
Bullous Impetigo
Non-bullous Impetigo
Ecthyma
Drug Induced
References
- ↑ Darmstadt GL, Lane AT (1994). “Impetigo: an overview”. Pediatr Dermatol. 11 (4): 293–303. PMID 7899177.
- ↑ Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC (1990). “Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies”. Am J Dis Child. 144 (12): 1313–5. PMID 2244610.
- ↑ 3.0 3.1 Stulberg DL, Penrod MA, Blatny RA (2002). “Common bacterial skin infections”. American family physician. 66 (1): 119–24. PMID 12126026.
- ↑ Cole C, Gazewood J (2007). “Diagnosis and treatment of impetigo”. Am Fam Physician. 75 (6): 859–64. PMID 17390597.
- ↑ Kikuta H, Shibata M, Nakata S, Yamanaka T, Sakata H, Akizawa K; et al. (2011). “Predominant Dissemination of PVL-Negative CC89 MRSA with SCCmec Type II in Children with Impetigo in Japan”. Int J Pediatr. 2011: 143872. doi:10.1155/2011/143872. PMC 3236481. PMID 22187567.
- ↑ Shi D, Higuchi W, Takano T, Saito K, Ozaki K, Takano M; et al. (2011). “Bullous impetigo in children infected with methicillin-resistant Staphylococcus aureus alone or in combination with methicillin-susceptible S. aureus: analysis of genetic characteristics, including assessment of exfoliative toxin gene carriage”. J Clin Microbiol. 49 (5): 1972–4. doi:10.1128/JCM.01742-10. PMC 3122639. PMID 21430094.
- ↑ Jenney A, Holt D, Ritika R, Southwell P, Pravin S, Buadromo E; et al. (2014). “The clinical and molecular epidemiology of Staphylococcus aureus infections in Fiji”. BMC Infect Dis. 14: 160. doi:10.1186/1471-2334-14-160. PMC 3998116. PMID 24655406.
- ↑ Cohen PR (2016). “Bullous impetigo and pregnancy: Case report and review of blistering conditions in pregnancy”. Dermatol Online J. 22 (4). PMID 27617460.
- ↑ Duggal SD, Bharara T, Jena PP, Kumar A, Sharma A, Gur R; et al. (2016). “Staphylococcal bullous impetigo in a neonate”. World J Clin Cases. 4 (7): 191–4. doi:10.12998/wjcc.v4.i7.191. PMC 4945591. PMID 27458596.
- ↑ Moran GJ, Amii RN, Abrahamian FM, Talan DA (2005). “Methicillin-resistant Staphylococcus aureus in community-acquired skin infections”. Emerg Infect Dis. 11 (6): 928–30. doi:10.3201/eid1106.040641. PMC 3367577. PMID 15963289.
- ↑ Kuniyuki S, Nakano K, Maekawa N, Suzuki S (2005). “Topical antibiotic treatment of impetigo with tetracycline”. J Dermatol. 32 (10): 788–92. PMID 16361729.
Differentiating Impetigo from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2], Usama Talib, BSc, MD [3]
Overview
Impetigo must be differentiated from other diseases that cause pustules surrounded by erythematous skin, including chickenpox, herpes zoster, erythema multiforme, among others. It should be differentiated from scabies, contact dermatitis, lupus (discoid type), herpes simplex, burns, necrotizing fasciitis.[1][2]
Differential Diagnosis
Different rash-like conditions can be confused with impetigo and are thus included in the differential diagnosis. The various conditions that should be differentiated from impetigo include:[1][2][3][4][5][6][7]
| Disease | Features |
|---|---|
| Impetigo | |
| Insect bites |
|
| Kawasaki disease |
|
| Measles |
|
| Monkeypox |
|
| Rubella |
|
| Atypical measles |
|
| Coxsackievirus |
|
| Acne |
|
| Syphilis | It commonly presents with gneralized systemic symptoms such as malaise, fatigue, headache and fever. Skin eruptions may be subtle and asymptomatic It is classically described as:
|
| Molluscum contagiosum |
|
| Mononucleosis |
|
| Toxic erythema | |
| Rat-bite fever | |
| Parvovirus B19 | |
| Cytomegalovirus |
|
| Scarlet fever |
|
| Rocky Mountain spotted fever |
|
| Stevens-Johnson syndrome |
|
| Varicella-zoster virus | |
| Chickenpox |
|
| Meningococcemia | |
| Rickettsial pox | |
| Meningitis |
|
References
- ↑ 1.0 1.1 Hartman-Adams H, Banvard C, Juckett G (2014). “Impetigo: diagnosis and treatment”. Am Fam Physician. 90 (4): 229–35. PMID 25250996.
- ↑ 2.0 2.1 Mehta N, Chen KK, Kroumpouzos G (2016). “Skin disease in pregnancy: The approach of the obstetric medicine physician”. Clin Dermatol. 34 (3): 320–6. doi:10.1016/j.clindermatol.2016.02.003. PMID 27265069.
- ↑ Moore, Zack S; Seward, Jane F; Lane, J Michael (2006). “Smallpox”. The Lancet. 367 (9508): 425–435. doi:10.1016/S0140-6736(06)68143-9. ISSN 0140-6736.
- ↑ Ibrahim F, Khan T, Pujalte GG (2015). “Bacterial Skin Infections”. Prim Care. 42 (4): 485–99. doi:10.1016/j.pop.2015.08.001. PMID 26612370.
- ↑ Ramoni S, Boneschi V, Cusini M (2016). “Syphilis as “the great imitator”: a case of impetiginoid syphiloderm”. Int J Dermatol. 55 (3): e162–3. doi:10.1111/ijd.13072. PMID 26566601.
- ↑ Kimura U, Yokoyama K, Hiruma M, Kano R, Takamori K, Suga Y (2015). “Tinea faciei caused by Trichophyton mentagrophytes (molecular type Arthroderma benhamiae ) mimics impetigo : a case report and literature review of cases in Japan”. Med Mycol J. 56 (1): E1–5. doi:10.3314/mmj.56.E1. PMID 25855021.
- ↑ CEDEF (2012). “[Item 87–Mucocutaneous bacterial infections]”. Ann Dermatol Venereol. 139 (11 Suppl): A32–9. doi:10.1016/j.annder.2012.01.002. PMID 23176858.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
In 2010, 140 million people suffered from impetigo. Impetigo is more common among children. Impetigo is more prevalent in tropical and pacific countries.[1][2][3]
Epidemiology and Demographics
Incidence
- In 2010, 140 million people suffered from impetigo.[3]
Prevalence
- The prevalence of impetigo in Australian Aboriginal communities is 49%.[2]
- The prevalence of impetigo in Solomon Islands is 43%.[4]
- Impetigo is more prevalent in tropical and pacific countries.[1][2]
- In 2006-2007, 25.6% school going children and 12.2% infants had active impetigo in Fiji.[1]
Age
- Impetigo is more common among young children between age 2 to 5. Particularly those who attend school or daycare centers.[5][6][1]
- A study showed that almost 69% of children below the age of 16 were affected by impetigo.[2]
- Non-bullous impetigo is rare in children under 2 years.[7]
Gender
- The distribution of impetigo is not effected by gender of the patient.
Race
- Impetigo is very common in Australian Aboriginal communities and Solomon Islands.[2]
References
- ↑ 1.0 1.1 1.2 1.3 “High Burden of Impetigo and Scabies in a Tropical Country”.
- ↑ 2.0 2.1 2.2 2.3 2.4 Romani L, Steer AC, Whitfeld MJ, Kaldor JM (2015). “Prevalence of scabies and impetigo worldwide: a systematic review”. Lancet Infect Dis. 15 (8): 960–7. doi:10.1016/S1473-3099(15)00132-2. PMID 26088526.
- ↑ 3.0 3.1 Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M; et al. (2012). “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet. 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
- ↑ Eason RJ, Tasman-Jones T (1985). “Resurgent yaws and other skin diseases in the Western Province of the Solomon Islands”. P N G Med J. 28 (4): 247–50. PMID 2940770.
- ↑ Hartman-Adams H, Banvard C, Juckett G (2014). “Impetigo: diagnosis and treatment”. Am Fam Physician. 90 (4): 229–35. PMID 25250996.
- ↑ Cohen PR (2016). “Bullous impetigo and pregnancy: Case report and review of blistering conditions in pregnancy”. Dermatol Online J. 22 (4). PMID 27617460.
- ↑ Pereira LB (2014). “Impetigo – review”. An Bras Dermatol. 89 (2): 293–9. PMC 4008061. PMID 24770507.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Impetigo is often associated with insect bites, cuts, and other forms of trauma to the skin. Humidity, obesity, corticosteroid use, chemotherapy, dysglobulinemias, leukemias and malnutrition are some other risk factors for impetigo.[1] Handwashing decreseas the incidence of impetigo by 34%.[2]
Risk Factors
Risk factors for impetigo include:[1][3][4][5][6][7][8]
- Abrasions
- Trauma
- Insect bite
- Herpes
- Scabies
- Children attending daycare
- Basic skin pH
- Lack of sebaceous secretions
- Humidity
- Obesity
- Corticosteroid use
- Chemotherapy
- Dysglobulinemias
- Leukemia
- Contact sports
- Chronic granulomatous disease
- Diabetes
- Malnutrition
- Congenital or acquired immunodeficiencies e.g. AIDS
- Temperature around 37 C
- Surgery
- Poor hygiene
References
- ↑ 1.0 1.1 Carroll JA (1996). “Common bacterial pyodermas. Taking aim against the most likely pathogens”. Postgrad Med. 100 (3): 311–3, 317–22. doi:10.3810/pgm.1996.09.84. PMID 8795661.
- ↑ Luby SP, Agboatwalla M, Feikin DR, Painter J, Billhimer W, Altaf A; et al. (2005). “Effect of handwashing on child health: a randomised controlled trial”. Lancet. 366 (9481): 225–33. doi:10.1016/S0140-6736(05)66912-7. PMID 16023513. Review in: Evid Based Med. 2006 Jun;11(3):88
- ↑ Oumeish I, Oumeish OY, Bataineh O (2000). “Acute bacterial skin infections in children”. Clin Dermatol. 18 (6): 667–78. PMID 11173202.
- ↑ Chiller K, Selkin BA, Murakawa GJ (2001). “Skin microflora and bacterial infections of the skin”. J Investig Dermatol Symp Proc. 6 (3): 170–4. doi:10.1046/j.0022-202x.2001.00043.x. PMID 11924823.
- ↑ Adams BB (2002). “Dermatologic disorders of the athlete”. Sports Med. 32 (5): 309–21. PMID 11929358.
- ↑ Hartman-Adams H, Banvard C, Juckett G (2014). “Impetigo: diagnosis and treatment”. Am Fam Physician. 90 (4): 229–35. PMID 25250996.
- ↑ SHOOTER RA, SMITH MA, GRIFFITHS JD, BROWN ME, WILLIAMS RE, RIPPON JE; et al. (1958). “Spread of staphylococci in a surgical ward”. Br Med J. 1 (5071): 607–13. PMC 2028078. PMID 13510743.
- ↑ Pereira LB (2014). “Impetigo – review”. An Bras Dermatol. 89 (2): 293–9. PMC 4008061. PMID 24770507.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
If left untreated, most cases of non-bullous impetigo resolve within 1-2 weeks. The complications of impetigo include poststreptococcal glomerulonephritis and rheumatic fever.[1][2][3][4][5]
Natural History
If left untreated, most cases of non-bullous impetigo resolve within 1-2 weeks. All forms of impetigo start as a lesion which then ruptures leading to variable pattern of crusting.[5][6][7][8]
Non-bullous Impetigo
- Non-bullous impetigo begins as a vesicle with erythematous base.
- The lesions are 1-2cm each and distant lesions can be seen because of its contagious nature.
- The vesicle ruptures easily forming a yellow exudate on the surface.
- This exudate dries to form a golden brown crust.
- Lymphadenopathy and fever may be observed.
- This is followed by complete recovery of the lesion.
- If left untreated, most cases of non-bullous impetigo resolve within 1-2 weeks.
Bullous Impetigo
- Bullus impetigo begins as smaller vesicles which form flaccid blisters.
- If left untreated the bullae are filled with clear fluid which turns yellow and less clearer later.
- Rupture of the bullae leaves a ring of golden crust.
- The bullous impetigo lesions are painful and associated with itching.
- The lesions of bullous impetigo are commonly seen on the trunk and the extremities.
- Bullous impetigo when left untreated for long, may lead to cellulitis, poststreptococcal glomerulonephritis or rheumatic fever.
Ecthyma
- Ecthyma starts as pus filled, painful lesions on the extremities.
- The lesions rupture to form a hard crust along with an ulcer that can involve deeper layers.
- The lesions of ecthyma may form a scar after their resolution.
Complications
The complications of impetigo include:[1][2][3][4][5][6]
- Recurrent impetigo
- Poststreptococcal glomerulonephritis
- Rheumatic fever
- Cellulitis
Prognosis
The prognosis of non-bullous impetigo is very good.
References
- ↑ 1.0 1.1 McDonald MI, Towers RJ, Andrews RM, Benger N, Currie BJ, Carapetis JR (2006). “Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic”. Clin Infect Dis. 43 (6): 683–9. doi:10.1086/506938. PMID 16912939.
- ↑ 2.0 2.1 Weinstein L, Le Frock J (1971). “Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomerulonephritis?”. J Infect Dis. 124 (2): 229–31. PMID 4942062.
- ↑ 3.0 3.1 Cohen PR (2016). “Bullous impetigo and pregnancy: Case report and review of blistering conditions in pregnancy”. Dermatol Online J. 22 (4). PMID 27617460.
- ↑ 4.0 4.1 Duggal SD, Bharara T, Jena PP, Kumar A, Sharma A, Gur R; et al. (2016). “Staphylococcal bullous impetigo in a neonate”. World J Clin Cases. 4 (7): 191–4. doi:10.12998/wjcc.v4.i7.191. PMC 4945591. PMID 27458596.
- ↑ 5.0 5.1 5.2 Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ (2011). “Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis”. Pediatr Nephrol. 26 (2): 165–80. doi:10.1007/s00467-010-1554-6. PMID 20652330.
- ↑ 6.0 6.1 Hartman-Adams H, Banvard C, Juckett G (2014). “Impetigo: diagnosis and treatment”. Am Fam Physician. 90 (4): 229–35. PMID 25250996.
- ↑ Nishifuji K, Shimizu A, Ishiko A, Iwasaki T, Amagai M (2010). “Removal of amino-terminal extracellular domains of desmoglein 1 by staphylococcal exfoliative toxin is sufficient to initiate epidermal blister formation”. J Dermatol Sci. 59 (3): 184–91. doi:10.1016/j.jdermsci.2010.07.010. PMID 20728315.
- ↑ Chiller K, Selkin BA, Murakawa GJ (2001). “Skin microflora and bacterial infections of the skin”. J Investig Dermatol Symp Proc. 6 (3): 170–4. doi:10.1046/j.0022-202x.2001.00043.x. PMID 11924823.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Related Chapters
Related Chapters
| File:Wiktionary-logo-en-v2.svg | Look up impetigo in Wiktionary, the free dictionary. |
External Links
External Links
de:Impetigo contagiosa id:Impetigo nl:Krentenbaard no:Brennkopper fi:Märkärupi sv:Impetigo
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
